|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/21 | |
| A61P 27/00 |
| (11) | Number of the document | 2916859 |
| (13) | Kind of document | T |
| (96) | European patent application number | 13792162.3 |
| Date of filing the European patent application | 2013-11-01 | |
| (97) | Date of publication of the European application | 2015-09-16 |
| (45) | Date of publication and mention of the grant of the patent | 2017-06-28 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2013/068056 |
| Date | 2013-11-01 |
| (87) | Number | WO 2014/071183 |
| Date | 2014-05-08 |
| (30) | Number | Date | Country code |
| 201261721810 P | 2012-11-02 | US |
| (72) |
MILLER, Sheldon S., US
MAMINISHKIS, Arvydas, US
REMÉ, Charlotte E., CH
|
| (73) |
Merck Patent GmbH,
Frankfurter Strasse 250, 64293 Darmstadt,
DE
The U.S.A. as represented by the Secretary, Department of Health and Human Services, Office of Technology Transfer National Institutes of Health 6011 Executive Boulevard, Suite 325, MSC 7660, Bethesda, MD 20892-7660, US |
| (54) | METHOD OF REDUCING ADVERSE EFFECTS IN A CANCER PATIENT UNDERGOING TREATMENT WITH A MEK INHIBITOR |
| METHOD OF REDUCING ADVERSE EFFECTS IN A CANCER PATIENT UNDERGOING TREATMENT WITH A MEK INHIBITOR |